<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Isoniazid hepatotoxicity</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Isoniazid hepatotoxicity</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Isoniazid hepatotoxicity</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne M Larson, MD, FACP, FAASLD, AGAF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy L Graziani, PharmD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Bernardo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">Isoniazid</a> (INH; isonicotinylhydrazide or isonicotinic acid hydrazine) is a synthetic antimycobacterial that inhibits cell wall synthesis and is potently bactericidal against replicating <em>Mycobacterium tuberculosis</em>. </p><p>INH has been associated with two syndromes of hepatotoxicity: mild INH hepatotoxicity and INH hepatitis [<a href="#rid1">1-4</a>]. It is the second most common drug causing liver injury [<a href="#rid5">5</a>].</p><p>Issues related to INH hepatotoxicity will be reviewed here. The clinical use of INH is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MILD INH HEPATOTOXICITY</span><span class="headingEndMark"> — </span>Mild INH hepatotoxicity refers to hepatic injury that is typically subclinical and asymptomatic. It is evidenced by transiently mildly elevated serum aminotransferases (usually &lt;100 international units/L or less than three-fold increase above the upper limit of normal [ULN]) [<a href="#rid5">5-7</a>]. It develops in up to 20 percent of patients treated with INH [<a href="#rid8">8-12</a>].</p><p>Adults are more likely to be affected than children; males and females appear to be equally vulnerable [<a href="#rid13">13</a>]. There is no relationship to race or the rate of hepatic acetylation of the drug.</p><p>Most cases are self-limited; in general, INH therapy can be continued with careful monitoring in the absence of dose adjustment. Typically, aminotransferase levels return to normal within several weeks after discontinuation of INH [<a href="#rid14">14,15</a>].</p><p class="headingAnchor" id="H3"><span class="h1">INH HEPATITIS</span><span class="headingEndMark"> — </span>INH hepatitis is a potentially fatal liver injury. It is usually symptomatic and may be fatal [<a href="#rid16">16,17</a>]. The occurrence is idiosyncratic and is not clearly related to dose or duration of therapy.</p><p class="headingAnchor" id="H4"><span class="h2">Prevalence and risk factors</span><span class="headingEndMark"> — </span>The risk of INH hepatitis associated with INH therapy for treatment of tuberculosis (TB) infection (latent TB) is 0.5 to 1.0 percent; INH hepatitis is fatal in 0.05 to 0.1 percent of cases [<a href="#rid5">5,18-23</a>].</p><p>Risk factors for the development of hepatotoxicity include [<a href="#rid5">5,19,24-33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased age [<a href="#rid19">19,31,34-38</a>] with an odds ratio for adverse events of 1.8 for individuals 35 to 64 years and 3.0 for individuals aged 65 to 90 years [<a href="#rid39">39</a>]. The severity of hepatotoxicity and mortality are also associated with increasing age [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regular alcohol intake [<a href="#rid19">19,25</a>]. It is possible that alcohol use may increase the risk of hepatotoxicity; one study noted development of hepatitis in 2.6 percent of patients treated with INH who drank alcohol daily [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent use of medications that induce CYP (P450) oxidative enzymes  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 1</a>) and/or are themselves hepatotoxic (eg, anticonvulsants, azole antifungals, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">pyrazinamide</a>, acetaminophen-containing preparations, lipid-lowering agents, herbal supplements, and others) [<a href="#rid1">1,41,42</a>]. Concurrent use of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> appears to promote formation of toxic INH metabolites [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Previous INH intolerance (eg, headaches, dizziness, nausea). Rechallenge with INH may result in recurrence of hepatotoxicity; however, some studies have shown that up to 80 percent of persons may be able to tolerate reintroduction of the drug [<a href="#rid43">43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior or concurrent liver disease, such as chronic viral hepatitis [<a href="#rid41">41,45-47</a>]. In one study of Vietnamese patients with hepatitis B treated with INH for latent tuberculosis infection, patients with HBeAg positivity were more likely to develop severe INH toxicity than patients who were HBeAg negative [<a href="#rid46">46</a>]. However, other studies have not observed an association between chronic viral hepatitis and risk for INH hepatotoxicity [<a href="#rid48">48</a>]. The presence of elevated liver enzymes is an independent risk factor for INH hepatotoxicity [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of peripheral neuropathy or presence of risk factors for peripheral neuropathy (eg, due to diabetes mellitus or alcoholism).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy and the immediate postpartum period with an odds ratio for hepatoxicity of 1.64 [<a href="#rid49">49</a>]. However, the data regarding risk to pregnancy outcomes remain inconsistent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Injection drug use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Female sex has been reported as a risk factor for hepatotoxicity; however not all studies have found this association [<a href="#rid34">34,37,50,51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic predisposition (particularly acetylator status) with three variant alleles on the N-acetyltransferase 2 (NAT2) gene leading to slow acetylation: position 481C&gt;T, position 590G&gt;A, and position 857G&gt;A [<a href="#rid52">52-57</a>]. Polymorphisms in cytochrome P450 2E1 have also been shown to predispose to hepatotoxicity. A sevenfold increased risk of hepatotoxicity has been noted in patients with CYP2E1 c1/c1 and slow-acetylator status [<a href="#rid53">53,58,59</a>]. Testing for NAT2 polymorphisms may allow for adjustment in drug dosing to improve therapeutic effect and to reduce toxicity [<a href="#rid60">60-64</a>]. (See <a class="local">'Mechanism of hepatotoxicity'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severely immunocompromised patients with advanced HIV infection [<a href="#rid65">65</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Clinical signs of INH hepatitis typically develop within the first two to three months after initiation of therapy, although they can occur as late as 14 months after initiation of therapy [<a href="#rid5">5,15,19,24</a>].</p><p>Clinical manifestations occur in up to 75 percent of patients and include fatigue, malaise, anorexia, and/or nausea, with or without vomiting [<a href="#rid8">8,34,66</a>]. Approximately one-third of patients have generalized flu-like symptoms, and some have right upper quadrant pain. Fever is seen in approximately 10 percent and rash in 5 percent of cases. Liver injury is typically hepatocellular; however, jaundice is a presenting feature in approximately 10 percent of cases and manifests days to weeks after onset of the above symptoms [<a href="#rid24">24,67</a>].</p><p>INH hepatitis may be associated with the development of severe hepatocellular necrosis and acute liver failure in up to 3 percent of cases. The clinical manifestations in this setting may include ascites, edema, and hepatic encephalopathy [<a href="#rid5">5,19,34</a>]. Liver enzymes &gt;10-fold upper limit of normal (ULN) and presence of encephalopathy of jaundice are poor prognostic signs. </p><p>The physical examination is largely nonspecific. Jaundice and abdominal pain may be present. Fever, rash, lymphadenopathy, and hepatomegaly are uncommon.</p><p>Laboratory evaluation characteristically demonstrates elevated aminotransferases (may be &gt;10 times the ULN) and variable elevations in alkaline phosphatase (usually &lt;2 times ULN), bilirubin, and prothrombin time [<a href="#rid34">34</a>].</p><p>Histologically, liver injury is predominantly hepatocellular in nature and ranges from focal mononuclear cell infiltrate to diffuse massive necrosis [<a href="#rid15">15,67,68</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of INH hepatitis should be suspected in patients taking INH who develop fatigue, malaise, anorexia, nausea, and/or vomiting in association with elevated serum aminotransferases. The diagnosis is established clinically, based on clinical manifestations and exclusion of other causes; the diagnosis is supported by resolution of elevated aminotransferases within several weeks after discontinuation of therapy [<a href="#rid3">3</a>].</p><p>There is overlap in the pattern of liver injury caused by INH and other antituberculosis agents including <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">pyrazinamide</a>; all individually or in combination may contribute to hepatotoxicity.</p><p>Clinical evaluation of patients with suspected INH hepatitis should include a complete clinical history regarding alcohol use and exposure to other potential hepatotoxins. Laboratory evaluation should include testing for viral hepatitis and autoimmune hepatitis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Additional issues related to diagnostic evaluation of drug-induced liver injury are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H12496295"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of INH hepatitis includes other causes of elevated aminotransferases (see  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Elevated serum aminotransferases'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Viral hepatitis – Viral hepatitis can occur as a result of infection due to hepatitis A, B, C, D, E, Epstein-Barr virus, cytomegalovirus, HIV, or other viral infections. The clinical manifestations are similar to those seen in INH hepatotoxicity and include fatigue, malaise, anorexia, nausea, and/or vomiting. The diagnosis is established via serology. (See related topics).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced liver injury – Drug-induced liver injury associated with medications or herbal therapies may present with mild, asymptomatic liver test abnormalities, cholestasis with pruritus, acute jaundice, or acute liver failure. The diagnosis is established clinically. (See  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune hepatitis – Clinical manifestations of autoimmune hepatitis include fatigue, anorexia, nausea, abdominal pain, and itching. INH can induce development antinuclear antibodies, even without hepatotoxicity. In the setting of INH hepatitis, autoantibody titers are generally low, and hypergammaglobulinemia is not seen, which helps to differentiate it from classic autoimmune hepatitis. The diagnosis of autoimmune hepatitis is based upon characteristic serologic and histologic findings. (See  <a class="medical medical_review" href="/z/d/html/3665.html" rel="external">"Overview of autoimmune hepatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ischemic injury – Ischemic hepatitis refers to diffuse hepatic injury resulting from acute hypoperfusion. Most patients have no symptoms referable to the liver but have marked elevation of the serum aminotransferase levels (exceeding 1000 international units/L or 50 times the upper limit of normal) after an episode of hypotension. (See  <a class="medical medical_review" href="/z/d/html/3593.html" rel="external">"Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy"</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Management</span><span class="headingEndMark"> — </span>Management of INH hepatitis consists of early recognition with timely discontinuation of INH and other potential hepatotoxins [<a href="#rid5">5</a>]. In severe cases, liver transplantation may be required [<a href="#rid19">19,69</a>].</p><p>In general, hepatitis attributed to antituberculosis drugs should prompt discontinuation of all hepatotoxic drugs if the serum bilirubin is ≥3 mg/dL or serum transaminases are more than five times the upper limit of normal  (<a class="graphic graphic_algorithm graphicRef109447" href="/z/d/graphic/109447.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef139067" href="/z/d/graphic/139067.html" rel="external">algorithm 2</a>) [<a href="#rid1">1,3</a>].</p><p>Once liver function tests return to baseline (or fall to less than twice normal), potentially hepatotoxic drugs can be restarted one at a time with careful monitoring between resumption of each agent  (<a class="graphic graphic_algorithm graphicRef109447" href="/z/d/graphic/109447.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef139067" href="/z/d/graphic/139067.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a>.)</p><p>The approach to regimen adjustment for drug intolerance is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Regimen adjustments for drug intolerance'</a>.)</p><p class="headingAnchor" id="H883838081"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>Use of INH should be limited to appropriate clinical circumstances, and patients should be educated about the signs and symptoms of hepatic toxicity; should toxicity be suspected, patients should be instructed to stop the medication and contact their provider [<a href="#rid3">3,19,70</a>].</p><p>Interest exists in development of newer formulations of INH which are less toxic. Examples include a cocrystal formulation (INH-quercetin), an alpha-lipoic acid formulation, hydrazide and aurone derivatives, and INH-a (INH-benzaldehyde) [<a href="#rid71">71-75</a>].</p><p>Issues related to clinical and laboratory monitoring for patients on INH for treatment of latent tuberculosis infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection", section on 'Monitoring and adherence'</a>.)</p><p>Issues related to clinical and laboratory monitoring for patients on INH and other antituberculous drugs for treatment of active tuberculosis infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/488.html" rel="external">"Antituberculous drugs: An overview", section on 'Clinical and laboratory monitoring'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>The overall case-fatality rate in patients who develop clinically apparent hepatitis is approximately 10 percent [<a href="#rid24">24</a>]. Older adult patients or those who present with INH hepatitis after taking the drug for more than two months have a worse prognosis [<a href="#rid7">7,24,76,77</a>]. Some studies have found a higher case-fatality rate among African-American patients than other patients, as well as a higher case-fatality rate among African-American females than African-American males [<a href="#rid24">24,31,66,78,79</a>].</p><p class="headingAnchor" id="H11"><span class="h1">MECHANISM OF HEPATOTOXICITY</span><span class="headingEndMark"> — </span>The mechanism of INH hepatotoxicity remains incompletely understood [<a href="#rid80">80</a>]. Toxicity is likely associated with metabolism of the drug [<a href="#rid24">24,80-82</a>]. Alternatively, liver injury may occur via induction of an immune response that causes liver injury [<a href="#rid83">83,84</a>].</p><p>INH is rapidly absorbed from the gastrointestinal tract and diffuses into all body tissues [<a href="#rid85">85</a>]. The presence of food in the stomach significantly hinders absorption [<a href="#rid86">86</a>]. The plasma concentration reaches its peak approximately one to three hours after ingestion of the medication [<a href="#rid80">80</a>]. Hepatic metabolism of INH creates numerous metabolites including isonicotinic acid (INA), hydrazine (HZ), ammonia, N1-acetyl-N2-isonicotinylhydrazide (AcINH or acetylINH), acetylhydrazine (AcHZ), diacetylhydrazine (DiAcHZ), and oxidizing free radicals [<a href="#rid87">87</a>]. These compounds are formed via three predominant reactions [<a href="#rid88">88</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Acyl amidase hydrolysis – Forming INA and HZ</p><p class="bulletIndent1"><span class="glyph">●</span>Cytochrome P450 oxidation – Forming HZ, ammonia, and free radicals</p><p class="bulletIndent1"><span class="glyph">●</span>N-acetyltransferase 2 (NAT2) activity – Forming AcINH, AcHZ, and DiAcHZ</p><p></p><p>AcHZ, toxic free radicals, and particularly hydrazine are the drug metabolites that have been most consistently implicated in the pathogenesis of INH hepatitis [<a href="#rid89">89,90</a>]. INH is first acetylated within the liver via NAT2 to form the inactive compound AcINH, which is then hydrolyzed to form AcHZ and INA [<a href="#rid87">87</a>]. AcHZ is usually further acetylated to the nontoxic derivative DiAcHZ and excreted in the urine [<a href="#rid17">17</a>]. It is also oxidized into ammonia by the liver, with contributions from the muscle, kidney, and brain [<a href="#rid87">87</a>]. In addition, AcHZ can be oxidized by the cytochrome P450 pathway to form toxic reactive acetyl free radicals that can form covalent bonds with liver cell macromolecules, interfering with their function and leading to hepatocellular necrosis and cell death [<a href="#rid7">7,8,52,81,89,91-93</a>]. Cytochrome isoforms 2E1, 2B1, and 1A1/A2 have been implicated in this process [<a href="#rid58">58,94,95</a>].</p><p>NAT2 is a phase II enzyme and is the primary enzyme involved in the metabolism of INH [<a href="#rid56">56</a>]. Deficiency of this enzyme has been associated with INH hepatotoxicity. The exact mechanism by which the NAT2 deficiency may cause hepatotoxicity is not known [<a href="#rid80">80</a>]. NAT2 is highly polymorphic, and these genetic polymorphisms are associated with trimodal pharmacokinetics of INH with three phenotypes: slow, intermediate, and fast acetylation [<a href="#rid75">75,96-100</a>]. The NAT2 polymorphisms significantly affect the plasma concentrations of INH, with fast acetylators having lower plasma concentrations than slow acetylators [<a href="#rid101">101,102</a>]. There is a strong association between the polymorphisms and risk of hepatotoxicity from INH [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/z/d/html/3568.html" rel="external">"Drugs and the liver: Metabolism and mechanisms of injury"</a>.)</p><p>Data on the association between acetylator phenotype and risk of INH hepatotoxicity remains conflicting [<a href="#rid9">9,27,29,59,76,88,92,104-112</a>]. Rapid acetylation of AcHZ should in theory reduce the formation of toxic AcHZ oxidative metabolites [<a href="#rid52">52</a>]. However, some have shown that rapid acetylators are more susceptible to liver injury due to increased production of hepatotoxins [<a href="#rid113">113</a>]. Studies have shown a higher rate of toxicity in slow acetylators carrying homozygous mutant alleles, leading to a higher concentration of AcHZ [<a href="#rid52">52-54,100,108,111,114-116</a>]. Meta-analysis has shown that genetic variants of NAT2 play a role in INH hepatotoxicity, particularly with three variant alleles: position 481C&gt;T, position 590G&gt;A, and position 857G&gt;A [<a href="#rid56">56,117</a>]. </p><p>Excess AcHZ is diverted into an alternate CYP pathway, resulting in the development of hepatotoxic metabolites. Data that show a higher risk of hepatitis when INH is combined with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> and other CYP inducers support this theory [<a href="#rid106">106</a>]. In one study, for example, NAT2 and CYP2E1 testing was performed in 89 patients receiving INH for treatment of latent tuberculosis [<a href="#rid58">58</a>]. NAT2 testing was not predictive of hepatotoxicity. However, the CYP2E1 *1a/*1a genotype (not CYP2E1 overall) significantly correlated with the development of elevated liver enzymes. Other data suggest that individuals carrying the CYP2E1 c1/c1 genotype are at greater risk for hepatotoxicity, particularly in the presence of slow acetylator NAT2 [<a href="#rid59">59</a>]. In a Chinese population, this genotype carried up to a 3.9-fold increased probability of hepatotoxicity in rapid acetylators and a 7.4-fold increased probability of hepatotoxicity in slow acetylators [<a href="#rid59">59,118,119</a>]. INH may also promote the development of hepatitis by inhibiting CYP2E and CYP2C, which could increase levels of other hepatotoxic drugs that are metabolized by these enzymes (eg, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>) [<a href="#rid3">3</a>].</p><p><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> is seldom hepatotoxic when used alone but increases the activity of the CYP system and thereby can increase the production of toxic metabolites from INH. Toxic hepatitis is seen with the combination of INH and rifampin more frequently (5 to 8 percent) than with either drug alone [<a href="#rid105">105,120-122</a>], and hepatitis occurs sooner, mainly during the first month [<a href="#rid122">122</a>]. (See  <a class="medical medical_review" href="/z/d/html/491.html" rel="external">"Rifamycins (rifampin, rifabutin, rifapentine)"</a>.)</p><p class="headingAnchor" id="H3816607"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/17191.html" rel="external">"Patient education: Drug-induced hepatitis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2810569"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">Isoniazid</a> (INH) is a synthetic antibiotic that is bactericidal against replicating <em>Mycobacterium tuberculosis</em>. INH has been associated with two syndromes of hepatotoxicity: mild INH hepatotoxicity and INH hepatitis. (See <a class="local">'Introduction'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild INH hepatotoxicity refers to hepatic injury that is typically subclinical and evidenced only by mildly elevated serum aminotransferases (usually &lt;100 international units/L). Most cases are self-limited; in general, INH therapy can be continued with careful monitoring. Typically, aminotransferase levels return to normal within several weeks after discontinuation of INH. (See <a class="local">'Mild INH hepatotoxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>INH hepatitis is a more serious liver injury syndrome than mild INH hepatotoxicity; it is usually symptomatic and may be fatal. It is an idiosyncratic reaction that is not clearly related to dose or duration of therapy. Risk factors are many and include age, alcohol use, use of concomitant hepatotoxic drugs, and prior or concurrent liver disease. (See <a class="local">'INH hepatitis'</a> above and <a class="local">'Prevalence and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations of INH hepatitis typically occur within the first two to three months after initiation of therapy but may occur later; they include fatigue, malaise, anorexia, and/or nausea, with or without vomiting. Approximately one-third of patients have generalized flu-like symptoms, and some have right upper quadrant pain. Jaundice is a presenting feature in approximately 10 percent of cases and manifests days to weeks after onset of the above symptoms. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of INH hepatitis should be suspected in patients taking INH who develop fatigue, malaise, anorexia, nausea, and/or vomiting in association with elevated serum aminotransferases. The diagnosis is established clinically, based on clinical manifestations and exclusion of other causes; the diagnosis is supported by resolution of elevated aminotransferases within several weeks after discontinuation of therapy. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical evaluation of patients with suspected INH hepatitis should include clinical history regarding alcohol use and exposure to other potential hepatotoxins. Laboratory evaluation should include testing for viral hepatitis and autoimmune hepatitis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of INH hepatitis consists of timely discontinuation of INH and other potential hepatotoxins. In general, hepatitis attributed to antituberculous drugs should prompt discontinuation of all hepatotoxic drugs if the serum bilirubin is ≥3 mg/dL or serum transaminases are more than five times the upper limit of normal  (<a class="graphic graphic_algorithm graphicRef109447" href="/z/d/graphic/109447.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef139067" href="/z/d/graphic/139067.html" rel="external">algorithm 2</a>). (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of INH should be limited to appropriate clinical circumstances, and patients should be educated about the signs and symptoms of hepatic toxicity. Issues related to clinical and laboratory monitoring for patients on INH are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection", section on 'Monitoring and adherence'</a> and  <a class="medical medical_review" href="/z/d/html/488.html" rel="external">"Antituberculous drugs: An overview", section on 'Clinical and laboratory monitoring'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a class="nounderline abstract_t">Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017; 64:e1.</a></li><li><a class="nounderline abstract_t">Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935.</a></li><li><a class="nounderline abstract_t">Saifei Lei, Ruizhi Gu, Xiaochao Ma. Clinical perspectives of isoniazid-induced liver injury. Liver Research 2021; 5:45.</a></li><li><a class="nounderline abstract_t">Hayashi PH, Fontana RJ, Chalasani NP, et al. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clin Gastroenterol Hepatol 2015; 13:1676.</a></li><li><a class="nounderline abstract_t">Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969; 71:1113.</a></li><li><a class="nounderline abstract_t">Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975; 68:181.</a></li><li><a class="nounderline abstract_t">Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976; 84:181.</a></li><li><a class="nounderline abstract_t">Yamada S, Tang M, Richardson K, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009; 10:1433.</a></li><li><a class="nounderline abstract_t">P V K, Palaian S, Ojha P, P R S. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal. Pak J Pharm Sci 2008; 21:51.</a></li><li><a class="nounderline abstract_t">Vieira DE, Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil. J Bras Pneumol 2008; 34:1049.</a></li><li><a class="nounderline abstract_t">Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135:1924.</a></li><li><a class="nounderline abstract_t">Devrim İ, Devrim F, Bayram N, et al. Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection. Minerva Pediatr (Torino) 2021; 73:184.</a></li><li><a class="nounderline abstract_t">Salpeter SR. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993; 159:560.</a></li><li><a class="nounderline abstract_t">Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol 2016; 81:1030.</a></li><li><a class="nounderline abstract_t">Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972; 106:357.</a></li><li><a class="nounderline abstract_t">Lauterburg BH, Smith CV, Todd EL, Mitchell JR. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 1985; 235:566.</a></li><li><a class="nounderline abstract_t">LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168:443.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010; 59:224.</a></li><li><a class="nounderline abstract_t">Chalasani N, Bonkovsky HL, Fontana R, et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology 2015; 148:1340.</a></li><li><a class="nounderline abstract_t">Stead WW, To T, Harrison RW, Abraham JH 3rd. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987; 107:843.</a></li><li><a class="nounderline abstract_t">Chan CH, Or KK, Cheung W, Woo J. Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin. J Med 1995; 26:43.</a></li><li><a class="nounderline abstract_t">Young H, Wessolossky M, Ellis J, et al. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts. Clin Infect Dis 2009; 49:424.</a></li><li><a class="nounderline abstract_t">Black M, Mitchell JR, Zimmerman HJ, et al. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69:289.</a></li><li><a class="nounderline abstract_t">Grönhagen-Riska C, Hellstrom PE, Fröseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118:461.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Core curriculum on tuberculosis. What the clinician should know, 4th ed. .S. Department of Health and Human Services, Public Health Services; Atlanta, 2000.</li><li><a class="nounderline abstract_t">Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9:511.</a></li><li><a class="nounderline abstract_t">Maddrey WC. Drug-related acute and chronic hepatitis. Clin Gastroenterol 1980; 9:213.</a></li><li><a class="nounderline abstract_t">Dickinson DS, Bailey WC, Hirschowitz BI, et al. Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol 1981; 3:271.</a></li><li><a class="nounderline abstract_t">Acocella G, Bonollo L, Garimoldi M, et al. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut 1972; 13:47.</a></li><li><a class="nounderline abstract_t">Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145:494.</a></li><li><a class="nounderline abstract_t">Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157:1871.</a></li><li><a class="nounderline abstract_t">Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.</a></li><li class="breakAll">Liver Tox: Isoniazid. https://livertox.nlm.nih.gov/Isoniazid.htm (Accessed on March 16, 2021).</li><li><a class="nounderline abstract_t">Mach J, Huizer-Pajkos A, Mitchell SJ, et al. The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats. Fundam Clin Pharmacol 2016; 30:23.</a></li><li><a class="nounderline abstract_t">Ronald LA, Campbell JR, Rose C, et al. Estimated Impact of World Health Organization Latent Tuberculosis Screening Guidelines in a Region With a Low Tuberculosis Incidence: Retrospective Cohort Study. Clin Infect Dis 2019; 69:2101.</a></li><li><a class="nounderline abstract_t">Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128:116.</a></li><li><a class="nounderline abstract_t">Fernández-Villar A, Sopeña B, Fernández-Villar J, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004; 8:1499.</a></li><li><a class="nounderline abstract_t">Campbell JR, Trajman A, Cook VJ, et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis 2020; 20:318.</a></li><li><a class="nounderline abstract_t">Pande JN, Singh SP, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51:132.</a></li><li><a class="nounderline abstract_t">Chang KC, Leung CC, Yew WW, et al. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008; 177:1391.</a></li><li><a class="nounderline abstract_t">Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995; 21:929.</a></li><li><a class="nounderline abstract_t">Durand F, Jebrak G, Pessayre D, et al. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf 1996; 15:394.</a></li><li><a class="nounderline abstract_t">Saukkonen J. Challenges in reintroducing tuberculosis medications after hepatotoxicity. Clin Infect Dis 2010; 50:840.</a></li><li><a class="nounderline abstract_t">Fernández-Villar A, Sopeña B, Vázquez R, et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003; 36:293.</a></li><li><a class="nounderline abstract_t">Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002; 97:1198.</a></li><li><a class="nounderline abstract_t">Yew WW. Risk factors for hepatotoxicity during anti-tuberculosis chemotherapy in Asian populations. Int J Tuberc Lung Dis 2001; 5:99.</a></li><li><a class="nounderline abstract_t">Bliven EE, Podewils LJ. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. Int J Tuberc Lung Dis 2009; 13:1054.</a></li><li><a class="nounderline abstract_t">Hamada Y, Figueroa C, Martín-Sánchez M, et al. The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98:502.</a></li><li><a class="nounderline abstract_t">Shu CC, Lee CH, Lee MC, et al. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis 2013; 17:934.</a></li><li><a class="nounderline abstract_t">Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975; 18:70.</a></li><li><a class="nounderline abstract_t">Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26:312.</a></li><li><a class="nounderline abstract_t">Xiang Y, Ma L, Wu W, et al. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. PLoS One 2014; 9:e85905.</a></li><li><a class="nounderline abstract_t">Seng KY, Hee KH, Soon GH, et al. Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. Antimicrob Agents Chemother 2015; 59:6791.</a></li><li><a class="nounderline abstract_t">Khan S, Mandal RK, Elasbali AM, et al. Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence. Biosci Rep 2019; 39.</a></li><li><a class="nounderline abstract_t">Stanley LA, Sim E. Update on the pharmacogenetics of NATs: structural considerations. Pharmacogenomics 2008; 9:1673.</a></li><li><a class="nounderline abstract_t">Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62:423.</a></li><li><a class="nounderline abstract_t">Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37:924.</a></li><li><a class="nounderline abstract_t">Donald PR, Parkin DP, Seifart HI, et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 2007; 63:633.</a></li><li><a class="nounderline abstract_t">Toure A, Cabral M, Niang A, et al. Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients. Toxicol Rep 2016; 3:826.</a></li><li><a class="nounderline abstract_t">Hong BL, D'Cunha R, Li P, et al. A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis. Clin Ther 2020; 42:e220.</a></li><li><a class="nounderline abstract_t">Yoo H, Chun Ji S, Cho JY, et al. A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators. Pharmacogenet Genomics 2021; 31:68.</a></li><li class="breakAll">A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosing for tuberculosis treatment. medRxiv. Available at: https://www.medrxiv.org/content/10.1101/2021.01.17.21249995v2 (Accessed on April 12, 2021).</li><li><a class="nounderline abstract_t">Ngongondo M, Miyahara S, Hughes MD, et al. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. J Acquir Immune Defic Syndr 2018; 78:54.</a></li><li><a class="nounderline abstract_t">Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med 1996; 164:486.</a></li><li><a class="nounderline abstract_t">Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973; 79:1.</a></li><li><a class="nounderline abstract_t">Reddy KR, Schiff ER. Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents. Gastroenterol Clin North Am 1995; 24:923.</a></li><li><a class="nounderline abstract_t">Farrell FJ, Keeffe EB, Man KM, et al. Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. Dig Dis Sci 1994; 39:2255.</a></li><li><a class="nounderline abstract_t">Israel HL, Gottlieb JE, Maddrey WC. Perspective: preventive isoniazid therapy and the liver. Chest 1992; 101:1298.</a></li><li><a class="nounderline abstract_t">Liu F, Wang LY, Yu MC, et al. A new cocrystal of isoniazid-quercetin with hepatoprotective effect: The design, structure, and in vitro/in vivo performance evaluation. Eur J Pharm Sci 2020; 144:105216.</a></li><li><a class="nounderline abstract_t">Castelo-Branco FS, de Lima EC, Domingos JLO, et al. New hydrazides derivatives of isoniazid against Mycobacterium tuberculosis: Higher potency and lower hepatocytotoxicity. Eur J Med Chem 2018; 146:529.</a></li><li><a class="nounderline abstract_t">Dragostin I, Dragostin OM, Samal SK, et al. New isoniazid derivatives with improved pharmaco-toxicological profile: Obtaining, characterization and biological evaluation. Eur J Pharm Sci 2019; 137:104974.</a></li><li><a class="nounderline abstract_t">Yang D, Taylor ZE, Handy S, et al. Identification of Anti-tuberculosis Compounds From Aurone Analogs. Front Microbiol 2020; 11:1004.</a></li><li><a class="nounderline abstract_t">Bhilare NV, Dhaneshwar SS, Mahadik KR, Dasgupta A. Co-drug of isoniazid and sulfur containing antioxidant for attenuation of hepatotoxicity and treatment of tuberculosis. Drug Chem Toxicol 2022; 45:850.</a></li><li><a class="nounderline abstract_t">Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978; 59:13.</a></li><li><a class="nounderline abstract_t">Bailey WC, Weill H, DeRouen TA, et al. The effect of isoniazid on transaminase levels. Ann Intern Med 1974; 81:200.</a></li><li><a class="nounderline abstract_t">Levin ML, Moodie AS. Isoniazid prophylaxis and deaths in Baltimore, Maryland 1972. Bull Int Union Tuberc 1976; 51:213.</a></li><li><a class="nounderline abstract_t">Long MW, Snider DE Jr, Farer LS. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119:879.</a></li><li><a class="nounderline abstract_t">Wang P, Pradhan K, Zhong XB, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B 2016; 6:384.</a></li><li><a class="nounderline abstract_t">Metushi IG, Nakagawa T, Uetrecht J. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chem Res Toxicol 2012; 25:2567.</a></li><li><a class="nounderline abstract_t">Chowdhury A, Santra A, Bhattacharjee K, et al. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 2006; 45:117.</a></li><li><a class="nounderline abstract_t">Metushi IG, Sanders C, Acute Liver Study Group, et al. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology 2014; 59:1084.</a></li><li><a class="nounderline abstract_t">Mahapatra S, Woolhiser LK, Lenaerts AJ, et al. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct. Antimicrob Agents Chemother 2012; 56:28.</a></li><li><a class="nounderline abstract_t">Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979; 4:401.</a></li><li><a class="nounderline abstract_t">Kumar AKH, Chandrasekaran V, Kumar AK, et al. Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. Indian J Med Res 2017; 145:530.</a></li><li><a class="nounderline abstract_t">Preziosi P. Isoniazid: metabolic aspects and toxicological correlates. Curr Drug Metab 2007; 8:839.</a></li><li><a class="nounderline abstract_t">Boelsterli UA, Lee KK. Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress. J Gastroenterol Hepatol 2014; 29:678.</a></li><li><a class="nounderline abstract_t">Nelson SD, Mitchell JR, Timbrell JA, et al. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 1976; 193:901.</a></li><li><a class="nounderline abstract_t">Sarich TC, Youssefi M, Zhou T, et al. Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Arch Toxicol 1996; 70:835.</a></li><li><a class="nounderline abstract_t">Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 1980; 213:364.</a></li><li><a class="nounderline abstract_t">Timbrell JA, Wright JM, Baillie TA. Monoacetylhydrazine as a metabolite of isoniazid in man. Clin Pharmacol Ther 1977; 22:602.</a></li><li><a class="nounderline abstract_t">Ono Y, Noda A, Zaima Y, et al. Determination of isonicotinic acid in the presence of isoniazid and acetylisoniazid. Studies on isonicotinic acid formation from isoniazid in isolated rat hepatocytes. J Chromatogr B Biomed Appl 1996; 677:339.</a></li><li><a class="nounderline abstract_t">Delaney J, Timbrell JA. Role of cytochrome P450 in hydrazine toxicity in isolated hepatocytes in vitro. Xenobiotica 1995; 25:1399.</a></li><li><a class="nounderline abstract_t">Sarich TC, Adams SP, Petricca G, Wright JM. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J Pharmacol Exp Ther 1999; 289:695.</a></li><li><a class="nounderline abstract_t">Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155:1717.</a></li><li><a class="nounderline abstract_t">Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9:29.</a></li><li><a class="nounderline abstract_t">Cordes H, Thiel C, Aschmann HE, et al. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy. Antimicrob Agents Chemother 2016; 60:6134.</a></li><li><a class="nounderline abstract_t">Sim E, Abuhammad A, Ryan A. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br J Pharmacol 2014; 171:2705.</a></li><li><a class="nounderline abstract_t">Walker K, Ginsberg G, Hattis D, et al. Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B Crit Rev 2009; 12:440.</a></li><li><a class="nounderline abstract_t">Wilkins JJ, Langdon G, McIlleron H, et al. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol 2011; 72:51.</a></li><li><a class="nounderline abstract_t">Donald PR, Sirgel FA, Venter A, et al. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis 2004; 39:1425.</a></li><li><a class="nounderline abstract_t">Heinrich MM, Zembrzuski VM, Ota MM, et al. Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil. Tuberculosis (Edinb) 2016; 101:15.</a></li><li><a class="nounderline abstract_t">Ellard GA, Mitchison DA, Girling DJ, et al. The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug. Am Rev Respir Dis 1978; 118:628.</a></li><li><a class="nounderline abstract_t">Pessayre D, Larrey D. Acute and chronic drug-induced hepatitis. Baillieres Clin Gastroenterol 1988; 2:385.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986; 6:295.</a></li><li><a class="nounderline abstract_t">Gurumurthy P, Krishnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129:58.</a></li><li><a class="nounderline abstract_t">Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35:883.</a></li><li><a class="nounderline abstract_t">Furet Y, Bechtel Y, Le Guellec C, et al. [Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism]. Therapie 2002; 57:427.</a></li><li><a class="nounderline abstract_t">Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol 2007; 3:1.</a></li><li><a class="nounderline abstract_t">Cai Y, Yi J, Zhou C, Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One 2012; 7:e47769.</a></li><li><a class="nounderline abstract_t">Huang YS. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J Chin Med Assoc 2014; 77:169.</a></li><li><a class="nounderline abstract_t">Leiro-Fernandez V, Valverde D, Vázquez-Gallardo R, et al. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis 2011; 15:1403.</a></li><li><a class="nounderline abstract_t">Ng CS, Hasnat A, Al Maruf A, et al. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol 2014; 70:1079.</a></li><li><a class="nounderline abstract_t">Teixeira RL, Morato RG, Cabello PH, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 2011; 106:716.</a></li><li><a class="nounderline abstract_t">Wang JY, Liu CH, Hu FC, et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 2011; 62:448.</a></li><li><a class="nounderline abstract_t">Fretland AJ, Leff MA, Doll MA, Hein DW. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 2001; 11:207.</a></li><li><a class="nounderline abstract_t">Guaoua S, Ratbi I, Laarabi FZ, et al. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population. BMC Genet 2014; 15:156.</a></li><li><a class="nounderline abstract_t">Jaramillo-Valverde L, Levano KS, Tarazona DD, et al. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients. Mol Genet Genomic Med 2022; 10:e1987.</a></li><li><a class="nounderline abstract_t">Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99:465.</a></li><li><a class="nounderline abstract_t">Lees AW, Allan GW, Smith J, et al. Toxicity form rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle 1971; 52:182.</a></li><li><a class="nounderline abstract_t">Emerit J, Decroix G, Chomette C, et al. Données nouvelles sur les hépitites observées au cours des traitements antituberculeux incluant la rifampicine. Revue Français des Maladies Respiratoires 1974; 2:565.</a></li></ol></div><div id="topicVersionRevision">Topic 477 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27932390" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17021358" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : An official ATS statement: hepatotoxicity of antituberculosis therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical perspectives of isoniazid-induced liver injury</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25724701" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5361410" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1080096" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/766682" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19761367" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166520" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19180340" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955056" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26377643" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8279152" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26773235" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mechanism of isoniazid-induced hepatotoxicity: then and now.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5080707" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Isoniazid-associated hepatitis. Report of an outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4078724" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746255" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Use of isoniazid for latent tuberculosis infection in a public health clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20203555" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3688677" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7561530" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19548835" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1150039" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Isoniazid-associated hepatitis in 114 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/707874" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/707874" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6391781" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical pharmacokinetics of the antituberculosis drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6994951" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Drug-related acute and chronic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7288121" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk factors for isoniazid (NIH)-induced liver dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5060669" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736764" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Isoniazid-associated hepatitis deaths: a review of available information.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620920" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764341" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764341" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26454000" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30856258" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Estimated Impact of World Health Organization Latent Tuberculosis Screening Guidelines in a Region With a Low Tuberculosis Incidence: Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16002924" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15636498" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31866327" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8711642" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18388355" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hepatotoxicity of pyrazinamide: cohort and case-control analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7705802" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8968694" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20156056" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Challenges in reintroducing tuberculosis medications after hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12539070" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Isoniazid hepatotoxicity among drug users: the role of hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12014728" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263525" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Risk factors for hepatotoxicity during anti-tuberculosis chemotherapy in Asian populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19723392" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32217619" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2295408" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Isoniazid-rifampin-induced hepatitis in hepatitis B carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23743313" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1149365" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21261721" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24465778" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26282412" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30509962" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018723" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Update on the pharmacogenetics of NATs: structural considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16770646" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668988" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17505821" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28959610" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33032843" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33165168" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33165168" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29406428" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8764622" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Isoniazid-related fatal hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4721174" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Isoniazid hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8749905" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7924752" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1582287" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Perspective: preventive isoniazid therapy and the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31945451" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A new cocrystal of isoniazid-quercetin with hepatoprotective effect: The design, structure, and in vitro/in vivo performance evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29407978" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : New hydrazides derivatives of isoniazid against Mycobacterium tuberculosis: Higher potency and lower hepatocytotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31252051" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : New isoniazid derivatives with improved pharmaco-toxicological profile: Obtaining, characterization and biological evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32508798" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Identification of Anti-tuberculosis Compounds From Aurone Analogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32543916" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Co-drug of isoniazid and sulfur containing antioxidant for attenuation of hepatotoxicity and treatment of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/345572" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4843577" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The effect of isoniazid on transaminase levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1030285" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Isoniazid prophylaxis and deaths in Baltimore, Maryland 1972.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/110184" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27709007" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Isoniazid metabolism and hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23016703" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16545483" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775837" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22037847" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/391461" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Clinical pharmacokinetics of isoniazid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28862186" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18220565" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Isoniazid: metabolic aspects and toxicological correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24783247" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7838" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8911642" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6767840" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/913027" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Monoacetylhydrazine as a metabolite of isoniazid in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8704939" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Determination of isonicotinic acid in the presence of isoniazid and acetylisoniazid. Studies on isonicotinic acid formation from isoniazid in isolated rat hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8719914" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Role of cytochrome P450 in hydrazine toxicity in isolated hepatocytes in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10215642" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9154882" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10667461" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27480867" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24467436" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20183529" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21320152" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15546075" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27865386" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/707886" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3044468" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Acute and chronic drug-induced hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3957235" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6367570" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11915035" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12611196" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : [Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17269890" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23082213" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24593909" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22283902" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24888881" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22012226" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21570123" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11337936" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25544508" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35751408" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1824929" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Toxic hepatitis with isoniazid and rifampin. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4255439" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Toxicity form rifampicin plus isoniazid and rifampicin plus ethambutol therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Données nouvelles sur les hépitites observées au cours des traitements antituberculeux incluant la rifampicine</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
